12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Melphalan delivered via Delcath's PHP system regulatory update

Delcath received CE Mark approval for its melphalan delivered using the Delcath Percutaneous Hepatic Perfusion (PHP) System to treat melanoma metastatic to the liver. Earlier...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >